Oracle seeks antidote for PeopleSoft poison pill

News

Oracle seeks antidote for PeopleSoft poison pill

Oracle appears to be gagging on one of the poison pills introduced by rival PeopleSoft, the company Oracle is attempting to acquire in a $7.3bn hostile takeover bid.

On Monday Oracle filed a request at the Delaware Chancery Court requesting an expedited ruling on its suit to block PeopleSoft's antitakeover provisions.

Oracle is highlighting the programme PeopleSoft initiated which offers customers a refund of up to five times the cost of PeopleSoft's software licences should PeopleSoft be bought out in the next two years and the purchasing company drops support for the applications within four years.

PeopleSoft recently amended the original refund offer, which triggered a fresh motion from some of its shareholders last week.

Oracle also offered an amended version of the poison pill suit on Monday, along with the expedition request. The company is arguing in court documents that the refund programme could make a takeover "prohibitive", not just for Oracle, but for any potential suitor. The liability incurred by this plan has already totalled $800m, according to public statements made by PeopleSoft.

Additionally, Oracle argued that these provisions would apply not just to a takeover by a third party, but by any transaction that changed PeopleSoft's ownership.

Oracle also claimed that the mechanism could be triggered if a majority of directors were elected over the next two years who were not approved by a majority of the incumbent board. This would frustrate Oracle's stated plans to get their own pro-acquisition directors elected next year.

"These and other provisions contained in the Revised Money Back Offer are so restrictive that no board could be assured that, through the exercise of any amount of care, they would not trigger them through the day-to-day exercise of their responsibility to manage the business and affairs of the company," Oracle said in its filing.

The net result of the money-back offer is that Oracle is "suffering direct and irreparable harm" and "may be forced to abandon its bid as it will no longer be economically reasonable".

In a statement yesterday, Oracle said, "PeopleSoft management's entrenchment tactics continue to destroy the value of the company for its shareholders. We remain committed to completing the transaction."

However, a PeopleSoft spokesman countered Oracle's assertion. "PeopleSoft's management is acting in the best interest of the shareholders," he insisted.

For instance, if Oracle were to buy out PeopleSoft, Oracle would be forced to support PeopleSoft's products. If someone else bought out PeopleSoft and discontinued the line, the customers would get up to five times what they paid for the licences, the spokesman said.

"How anyone can say it's not good for customers is a mystery to me. We think it's very positive for customers and very positive for shareholders."

Marc L Songini writes for Computerworld


Email Alerts

Register now to receive ComputerWeekly.com IT-related news, guides and more, delivered to your inbox.
By submitting you agree to receive email from TechTarget and its partners. If you reside outside of the United States, you consent to having your personal data transferred to and processed in the United States. Privacy
 

COMMENTS powered by Disqus  //  Commenting policy